2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Outstanding mix of clinical abstracts, including clinical trials, retrospective analysis, and molecular observations in myelofibrosis, polycythemia vera, essential thrombocythemia and other myeloid neoplasms
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Omics Technologies, Pathology, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

2039 Genomic profiling affects the outcome in 124 patients with blast-phase of BCR::ABL-negative myeloproliferative neoplasms

Davide Bonometti, Barbara Mora, MD2, Daniele Cattaneo, MD3, Claudia Maria Basilico4, Elena Tagliaferri5, Mariarita Sciumè6, Marta Lionetti, PhD7, Paola Bianchi, PhD8, Elisa Fermo9, Margherita Maffioli10, Kordelia Barbullushi, MD11, Francesco Versino, MD12, Lorenza Bertù13, Francesco Orsini14, Giorgio Alberto Croci Sr, MD15, Stefano Fiori, MD16, Francesca Magnoli, MD17, Akihiro Maeda18, Juan Carlos Entizne19, Riccardo Mario Colombo20, Giorgia Natascia Saporiti, MD, PhD21, Niccolo Bolli, MD, PhD22, Marta Coscia, MD, PhD23, Nicola Stefano Fracchiolla, MD24, Alessandra Iurlo, MD25, Francesco Passamonti, MD26
1 University of Milan, Milan, Italy
2 Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
3 Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
4 ASST Sette Laghi, Ospedale di Circolo, Varese, Italy
5 Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
6 Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
7 University of Milan, Milan, Italy
8 Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
9 Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
10 ASST Sette Laghi, Ospedale di Circolo, Varese, Italy
11 Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
12 Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
13 University of Insubria, Varese, Italy
14 ASST Sette Laghi, Ospedale di Circolo, Varese, Italy
15 Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, University of Milan, Milan, Italy
16 Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
17 ASST Sette Laghi, Ospedale di Circolo, Varese, Italy
18 Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
19 Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
20 Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
21 Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
22 Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, University of Milan, Milan, Italy
23 ASST Sette Laghi, Ospedale di Circolo, Varese, Italy, University of Insubria, Varese, Italy
24 Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
25 Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
26 Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, University of Milan, Milan, Italy

Background and aims: Blast-phase (BP) of BCR::ABL-negative myeloproliferative neoplasms (MPN) is associated with a dismal outcome. In most instances, MPN-BP is driven by the acquisition of additional myeloid neoplasms-associated cancer gene variants (CGVs) and cytogenetic abnormalities. In this study we characterized the genomic profile and define the outcome of a cohort of 124 patients with MPN-BP.

Study Population: We retrospectively evaluated 124 consecutive patients with MPN-BP (2022 WHO criteria), diagnosed between October 2006 and April 2026, with available information on clinical features, treatments, and outcome.  At BP diagnosis, conventional karyotype analysis and a myeloid NGS panel were performed on peripheral blood or bone marrow (BM) in 79 (63.7%) and 60 (48.4%) of cases, respectively. To note, only (likely-) pathogenic CGVs with their variant allele frequency (VAF, ≥2%) were reported.

Results: Median age at MPN-BP diagnosis was 71.4 years (range, 45.2–97.1) 65 (56.5%) of patients were males. Previous MPN type was primary myelofibrosis (PMF) in 53 (42.7%), post polycythemia vera (PV)/post essential thrombocythemia (ET) -MF (namely secondary MF) in 36 (29.0%), PV in 19 (15.3%), ET in 15 (12.1%), MPN-NOS in 1 (0.8%) patient. One subject had accelerated phase (AP)-PMF. The median interval between previous MPN and BP was 10.2 years (range, 0.3–39.3). MPN-driver mutation was JAK2 in 82 (66.1%), CALR in 25 (20.2%), MPL in 4 (3.2%) patients, with 11 (8.9%) triple-negative and 2 (1.6%) double mutated cases. Among JAK2-positive patients, median VAF at BP diagnosis was 49.6% (range, 3.1-97.3). Karyotype was normal (NK) in 20 cases (25.3%), while 15 (19%) displayed a single abnormality, 12 (15.2%) a double abnormality and 32 (40.5%) a complex karyotype (CK).  Median CGVs number/person was 3 (range, 0-7), with 45 (75.0%) subjects harboring ≥2 CGVs. The most frequent (≥5% of patients) CGVs were: TP53(n=19; 31.7%), ASXL1 (n=16; 26.7%), TET2 (n=16; 26.7%), DNMT3A (n=12; 20%), IDH1/2 (n=12; 20%), SRSF2 (n=11; 18.3%), RUNX1 (n=10; 16.7%), U2AF1 (n=7; 11.7%), NRAS (n=6; 10%), EZH2 (n=6; 10%), CBL (n=5; 8.3%), STAG2 (n=4; 6.7%), SETBP1 (n=3; 5%), ETV6 (n=3; 5%), and CUX1 (n=3; 5%). Of note, 8 (42.1%) TP53-mutated cases were multihit (2022 ICC criteria). At least one high-risk molecular alteration according to the 2022 ELN criteria (PMID: 35797463) was found in 46 (76.7%), with 23 (38.3%) subjects harboring ≥2 of those mutations. Besides, 39 (65%) subjects showed at least one genetic abnormality as for MIPSS70+ v2.0 (PMID: 29708808). No statistically significant difference in CGVs distribution was observed across MPN subtypes, except for TET2 (p=0.03). Considering the 108 patients with information on treatments, 24 (22.2%) received intensive chemotherapy (IC), 33 (30.6%) non-intensive treatment (NIT), and 51 (47.2%) best supportive care (BSC). Complete response (CR) was achieved by 55.0% of cases treated with IC and 40.0% with NIT, while partial response was respectively reached in 20.0% and 16.0% of subjects. A total of 15 (13.9%) patients received an allo-HSCT at a median time of 13 months (range, 4.1–40.2) from BP. In all cases, allo-HSCT was performed after achieving disease control - 10 (66.7%) in first CR. At a median follow-up of 3.4 months (range, 0.2-136.3) from BP diagnosis, 102 (82.3%) patients died; the median overall survival (OS) was 4.4 months (95%CI, 2.7-5.5). Median OS varied by first-line treatment assigned: 5.7 months (95%CI, 2.8-29.5) with IC, 4.9 months (95%CI, 3.4-18.5) with NIT, and 1.6 months (95%CI, 0.9-2.7) with BSC (p<0.001). Median OS after allo-HSCT was 74.6 months (95%CI, 13.8-NR), with 11 (73.3%) patients alive at last follow-up and 10 (90.9%) of them still in CR. We found an inverse association between survival and number of CGVs, with a median OS of 8.0 (95%CI, 2.5-NR), 5.4 (95%CI, 1.8-10.7) and 1.4 (95%CI, 1.0-NR) months for 0-1, 2-3, and ≥4 CGVs (p=0.02), respectively. Moreover, also cytogenetic risk groups influenced outcome with a median OS varying from 6 months (95%CI, 0.9–NR) to 2.2 months (95%CI, 1.6–4.4) for patients having NK and CK, respectively (p<0.001).

Conclusions: Our study shows that MPN-BP is characterized by the presence of high-risk myeloid mutations in around 75% and complex karyotype in 40% of patients.  Molecular and cytogenetic complexity is associated with a more aggressive disease. Correlative analyses between the most frequent CGVs and treatment outcomes are ongoing.

Davide Bonometti: No relevant conflicts of interest to declare.